News

Stay Up-To-Date on NEXT Oncology

Video: Expanded Phase 1 Program to the Dallas Area

In this video hosted by Oncology Tube, Anthony Tolcher, MD, discusses Cancer Drug Research: Expanded Phase 1 Program to the Dallas Area. iFrame is not supported!

SA cancer research company entering Dallas market as it eyes more U.S., European expansion

A cancer research company based in San Antonio is entering the Dallas market as it eyes more U.S. and European expansion… Read the full article at the San Antonio Business ...

First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma

SAN FRANCISCO and SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a clinical-stage precision oncology company, today announced positive monotherapy dose escalation data for its ...

MatTek and NEXT Oncology Announce Licensing Agreement

The Boston-based biotech company will use an inventory of patient-derived cancer cells to develop new lab-grown tumor models to accelerate and refine oncology research, and provide more targeted treatments for ...

NEXT Oncology Expands Phase I Program to Dallas Area

Expansion makes new break-through anticancer therapies closer to home for more Texans (DALLAS) April 12, 2023 –– Internationally known cancer researcher, Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, ...

Phase 1 Trial of DK210 Begins Dosing Patients With EGFR+ Solid Tumors

The first patient has been dosed with DK210 in a first-in-human, phase 1 clinical trial (NCT05704985) for patients with EGFR-expressing advanced solid tumors.1 “The Diakine™ platform combines the potent anti-cancer function ...

Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that discovers novel target-antibody pairs through its unbiased interrogation of the human immune response, today announced the formation of an ...

Syneos Health Partners with Equicare, Optimizing Data Capture and Integration to Accelerate Clinical Trial Research

MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Equicare to use proXimity™, an innovative cloud-based ...

Grand Opening of joint venture brings access to proprietary Phase I program to more patients

NEXT-Virginia Opens Phase I Clinical Research Clinic for Oncology Patients in collaboration with Virginia Cancer Specialists. (SAN ANTONIO) January 9, 2023 –– Dr. Alexander I. Spira of Virginia Cancer Specialists (VCS) ...

ONXEO provides update on the Development Program for its first-in-class drug candidate AsiDNATM

Paris (France), January 25th, 2023 – 6pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter “Onxeo” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative tumor ...